Universitaetsklinikum Schleswig-Holstein
Universitaetsklinikum Schleswig-Holstein is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Universitaetsklinikum Schleswig-Holstein?
The 2026-10-09 snapshot links Universitaetsklinikum Schleswig-Holstein to 3 distinct CTIS trials. Recorded services include Biomarker (ASO-PCR), Laboratory services, Ship to Address (For Aliq B). These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universitaetsklinikum Schleswig-Holstein?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universitaetsklinikum Schleswig-Holstein conducted?
The linked trials record locations in 20 countries, including Germany, Spain, France, Italy, Austria. These are trial locations, not confirmed office locations or countries where Universitaetsklinikum Schleswig-Holstein delivered services.
What can this page tell me about Universitaetsklinikum Schleswig-Holstein's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universitaetsklinikum Schleswig-Holstein. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universitaetsklinikum Schleswig-Holstein